Similar articles

• [Say no to the extremes in the debate on lipid reduction].

  Hjemdahl P, Allhammar A, Eklund J, Forslund T, Hulting J, Kahan T, Martinsson A, Malmström R, Rücker F, Schenck-Gustafsson K, Schwieler J, Törnerud M, Wettermark B. Hjemdahl P, et al. Lakartidningen. 2011 Sep 7-13;108(36):1664-5. Lakartidningen. 2011. PMID: 22032007 Swedish. No abstract available.
• [Strengthened support for statin therapy as secondary prevention. Doubtful evidence for more intensive lowering of cholesterol levels].

  Håkansson J. Håkansson J. Lakartidningen. 2011 Jun 1-14;108(22-23):1234-5. Lakartidningen. 2011. PMID: 21786497 Swedish. No abstract available.
• Is intensive LDL-cholesterol lowering beneficial and safe?

  Cheung BM, Lam KS. Cheung BM, et al. Lancet. 2010 Nov 13;376(9753):1622-4. doi: 10.1016/S0140-6736(10)61545-0. Epub 2010 Nov 8. Lancet. 2010. PMID: 21067806 No abstract available.
• [Better with lower LDL cholesterol! Aim at 2 mmol/l for secondary prevention].

  Olsson AG. Olsson AG. Lakartidningen. 2006 Jan 11-17;103(1-2):22-3. Lakartidningen. 2006. PMID: 16465841 Review. Swedish. No abstract available.
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Grundy SM, et al. J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001. J Am Coll Cardiol. 2004. PMID: 15358046 Review.